Content
All Posts > Content under Pharma/Biotech
Week In Review: Illumina Pays $8 Billion To Acquire GRAIL, An Early-Stage Cancer Testing Company
Article By:
ChinaBio® Today
Read
Saturday, September 26, 2020 1:33 PM EDT
Illumina will acquire Grail, an Illumina spin-out that is developing an early screening test for multiple forms of cancer, for $8 billion in cash and stock. JD Health, a Beijing online healthcare company, plans to raise $3 billion in a Hong Kong IPO.
J&J In Final Stage COVID-19 Tests: Would You Take The Vaccine?
Article By:
Mish Shedlock
Read
Thursday, September 24, 2020 4:20 AM EDT
Johnson & Johnson (JNJ) starts a 60,000 person phase-3 trial test. Stage-3 is the final phase.
Open Source Licensing Could Keep Big Pharma From Making Huge Profits Off Taxpayer-Funded Research
Article By:
The Conversation
Read
Wednesday, September 23, 2020 5:25 AM EDT
An international, multi-billion-dollar race is underway to develop a COVID-19 vaccine, and progress is moving at record speed, but with nationalistic, competitive undertones.
Market Briefing For Tuesday, Sept. 22
Article By:
Gene Inger
Read
Tuesday, September 22, 2020 2:25 AM EDT
Technical correction progression - keeps formerly 'hot stocks in cold storage' for at least now. Rebounds will occur of course, just as expected late Monday or during part of Tuesday's session.
Time For The Newer Biotech Companies To Wake Up?
Article By:
Michele Schneider
Read
Sunday, September 20, 2020 11:09 AM EDT
With companies like Pfizer giving possible hope for an end of year vaccine and a recent gap up in IBB (Nasdaq Biotechnology ETF), now could be a good time to keep an eye on newer issues in this sector.
Week In Review: Zai Lab To Raise Up To $845 Million In Hong Kong IPO
Article By:
ChinaBio® Today
Read
Saturday, September 19, 2020 1:56 PM EDT
Zai Lab of Shanghai is conducting a Hong Kong IPO that is expected to raise up to $845 million, offering 12.3% of the company's expanded number of shares. On the Nasdaq Exchange, Zai has a market capitalization of $6.2 billion.
Here's A Conservative Way To Invest In Pot Stocks
Article By:
Lorimer Wilson
Read
Friday, September 18, 2020 1:20 PM EDT
Seven major consumer and pharmaceutical corporations have bought into marijuana companies. Let's compare their stock performances YTD with those of their marijuana partners.
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
Article By:
Moon Kil Woong
Read
Friday, September 18, 2020 12:10 PM EDT
This is to clarify the recent conference call and counter misleading information on it by shorters etc.
Federal Reserve Predicts No Rate Increase Until End Of 2023
Article By:
Adam Vettese
Read
Thursday, September 17, 2020 5:58 AM EDT
On Wednesday the Fed said it won’t be raising interest rates from their near-zero level for years. After a two-day policy meeting, the bank released new projections in which 13 of 17 officials said they expect to keep rates near zero until 2023.
Is Bio-Tech Creating A Head & Shoulders Topping Pattern?
Article By:
Chris Kimble
Read
Wednesday, September 16, 2020 9:25 AM EDT
Biotech ETF (IBB) has performed better than the S&P 500, by nearly 9% this year, which sends a short-term bullish message.
In this article: IBB